Table 3.
Evaluation of polygenic risk score in prostate cancer screening in the subset of FinRSPC cohort.
| PRS | PSA < 4 ng/mL | PSA ≥ 4 ng/mL | % of men with PSA ≥ 4 ng/mL in different quartiles (p < 0.00001) | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| A) Association between quartile of polygenic risk score and PSA | |||||
| Q1 (n = 713) | 654 | 27 | 59 | 15 | 8.3% |
| Q2 (n = 711) | 623 | 25 | 88 | 22 | 12.4% |
| Q3 (n = 717) | 592 | 24 | 125 | 31 | 17.4% |
| Q4 (n = 707) | 575 | 24 | 132 | 33 | 18.7% |
| Risk factor | SIMPLE MODEL | MULTIPLE MODEL | |||
|---|---|---|---|---|---|
| OR (95% CI, p) | AUC (95% CI, p) | OR (95% CI) | AUC cumulative (95% CI, p) | ||
| B) Simple and multiple logistic regression models including PSA, age, polygenic risk score and their predictive performance to predict prostate cancer | |||||
| PSA | 6.50 (5.43–7.80, 2.61E-90) | 0.981 (0.97–0.99, 3.17E-232) | 6.60 (5.48–7.95, 8.29E-28) | 0.982 (0.97–0.99, 2.70E-232) | |
| Age | 1.04 (1.01–1.07, 0.016) | 0.557 (0.53–0.59, 0.000116) | 1.02 (0.94–1.11, 0.683) | 0.557 (0.53–0.59,0.000116) | |
| PRS | 1.06 (1.04–1.07, 1.59E-10) | 0.597 (0.57–0.63, 4.42E-11) | 1.05 (1.00–1.11, 0.038) | 0.600 (0.57–0.63, 1.80E-11) | |
P value based on χ2 test; PRS, polygenic risk score; PSA, prostate-specific antigen; Q, quartile.
OR = odds ratio; CI = confidence interval; AUC = area under the receiver operating characteristics curve; PRS, polygenic risk score; Predictive performance was assessed using the AUC for individual risk factors and for the genetic model including all risk factors. AUC cumulative denotes AUC values obtained when one risk factor at the time was added to the model from PSA only to a model including all risk factors. PSA, Age, PRS were used as continuous variables. Men aged 55–67 years at the enrollment to the FinRSPC trial.